Grifols SA ADR Dossier
Qualitative Analysis
Business overview
Grifols SA is a Barcelona-headquartered global healthcare company and a leading producer of plasma-derived medicines. The company operates primarily through its Biopharma segment, which represents over 86% of total turnover and is heavily anchored in the United States. Grifols specializes in the collection of human plasma and the manufacturing of essential therapies used to treat rare, chronic, and life-threatening conditions across immunology, hepatology, intensive care, pulmonology, and infectious diseases. The company maintains a vast network of plasma donation centers globally.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Segmenting the product portfolio to drive profitable growth. Focuses on growing immunoglobulins in the U.S. market, recapturing market share, and expanding subcutaneous IG (SCIG) growth, while focusing on higher-margin European markets and reducing exposure to lower-margin regions.
Expected impact: Mid-to-high single-digit momentum in immunoglobulins and strong double-digit subcutaneous IG growth.
Expanding ex-U.S. sourcing capabilities to build self-sufficiency and local resilience, highlighted by major projects in Egypt and Canada. The goal is to scale ex-U.S. collections by 2.5 times by 2029, allowing 100% of U.S. plasma to be allocated domestically.
Expected impact: Reduces dependence on the U.S. as a sole source of plasma supply and improves overall plasma economics.
Optimizing plasma sourcing mix, improving donor center performance through digitalization, and driving end-to-end immunoglobulin yield improvements across collection and manufacturing networks.
Expected impact: Reduces cost per liter of plasma and supports EBITDA margin expansion toward the 25% target.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To fully integrate Biotest's operations, capture significant revenue and cost synergies, and streamline corporate governance by delisting the subsidiary from the Frankfurt Stock Exchange.
Financial impact: The transaction was settled for a total cost of ’108 million, funded through available financial resources.
Strategic Partnerships
Key to expanding Grifols' global reach and commercial presence in the Chinese market.
Terms: Not fully disclosed
Collaboration for the opening and management of 28 plasma collection centers through the joint arrangement Biotek America LLC.
Terms: Executed through Biotek America LLC